Shares of Becton, Dickinson and Company (NYSE:BDX) opened at $211.58, and ended -0.03% lower at $210.97. Nearly 0.95 million shares were traded by the close, lower than its average daily volume of 1.14 million shares.Becton, Dickinson and Company (BDX) Analyst Opinion
Becton, Dickinson and Company has a consensus outperform rating from 15 Wall Street analysts, and the number of shares currently sold short amount to at least 5.9% of shares outstanding. The stock spiked 9.2% last month and is up 27.44 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover BDX having a buy-equivalent rating. Analysts have placed a $219 price target on Becton, Dickinson and Company, suggesting a 3.81% gain from recent close. It’s currently trading about -1.75% below its 52-week high.Becton, Dickinson and Company Earnings Surprise
Becton, Dickinson and Company (BDX) surprised the stock market in its last reported earnings when it earned $2.46 a piece versus the consensus-estimated $2.44. Its revenue totaled $3.06 billion up 3.04% from the previous quarter.Becton, Dickinson and Company (NYSE:BDX) Intraday View
This stock (BDX) is ahead of its 52-week low with 30.8%. Its last month’s stock price volatility remained 1.61% which for the week stands at 1.28%. The share price has moved forward from its 20 days moving average, trading at a distance of 5.66% and stays 6.11% away from its 50 days moving average. Over the last five days, shares have managed 3.89% gains and now is up 11.2% since hitting its 200-day moving average of $194.36. Becton, Dickinson and Company (BDX) has made its way to a 12-month gain of 22.54%.
Turning to Five Prime Therapeutics, Inc. (NASDAQ:FPRX), its shares were trading at $44.84 a retreat of $-1.07, on the trading floor. The stock, after opening at $45.67, touched a high of $46.41 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.4. Five Prime Therapeutics, Inc. has 5 buy ratings, 0 holds and 0 sells even after the stock tumbled -26.47% from its high of $ 60.98 to a $1.28 billion market value through last close.Five Prime Therapeutics, Inc. (FPRX) Consensus Price Target
The company’s consensus rating on Reuter’s scale slipped from 1.56 to 1.44 during a month. Analysts set a 12-month price target of $61.44 a share. The target implies a 37.02% spike from where the shares are currently trading. Also, the current price highlights a discount of 109.63% to analysts’ high consensus price target.Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Intraday Trading
The counter witnessed a trading volume of 0.25 million shares versus an average volume of 0.33 million shares during last trading session. Its last month’s stock price volatility remained 3.01% which for the week approaches 4.56%. The lowest price the stock reached in the last trading day was $44.68 and compares with the $25.97 52-week low. The stock recovered 72.66% since its low point and has performed -10.52% year-to-date.